The effect of normovolemic modified ultrafiltration on inflammatory mediators, endotoxins, terminal complement complexes and clinical outcome in high-risk cardiac surgery patients

Perfusion (United Kingdom)

Volumn 28, Issue 4, 2013, Pages 306-314

  Papadopoulos, N ^a   Bakhtiary, F ^b   Grun V ^a   Weber, C F ^a   Strasser, C ^a   Moritz, A ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; ENDOTOXIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTIC ACID; LIPOPOLYSACCHARIDE BINDING PROTEIN; TERMINAL COMPLEMENT COMPLEX; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AGED; ANESTHESIA INDUCTION; ARTICLE; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CHEST TUBE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART SURGERY; HIGH RISK PATIENT; HUMAN; MALE; NORMOVOLEMIC MODIFIED ULTRAFILTRATION; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; ULTRAFILTRATION;

ACUTE-PHASE PROTEINS; AGED; AGED, 80 AND OVER; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CARRIER PROTEINS; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINES; ENDOTOXINS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; ULTRAFILTRATION;

EID: 84879371475     PISSN: 02676591     EISSN: 1477111X     Source Type: Journal    
DOI: 10.1177/0267659113478450     Document Type: Article

References (27)

1. Morariu AM, Loef BG, Aarts LP, et al. Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury. Chest. 2005 ; 128: 2677-2687
2. Abdel-Rahman U, Ozaslan F, Risteski PS, et al. Initial experience with a minimized extracorporeal bypass system: is there a clinical benefit?. Ann Thorac Surg. 2005 ; 80: 238-243
3. Gourlay T. Biomaterial development for cardiopulmonary bypass. Perfusion. 2001 ; 16: 381-390
4. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 2003 ; 75: 715-720
5. Peschel T, Schönauer M, Thiele H, et al. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail. 2003 ; 5: 609-614
6. Sandek A, Bjarnason I, Volk HD, et al. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol. 2010 ; 157: 80-85
7. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999 ; 353: 1838-1842
8. Chew MS, Brix-Christensen V, Ravn HB, et al. Effect of modified ultrafiltration on the inflammatory response in paediatric open-heart surgery: a prospective, randomized study. Perfusion. 2002 ; 17: 327-333
9. Luciani GB, Menon T, Vecchi B, et al. Modified ultrafiltration reduces morbidity after adult cardiac operations: a prospective, randomized clinical trial. Circulation. 2001 ; 12: 253-259
10. Kiziltepe U, Uysalel A, Corapcioglu T, et al. Effects of combined conventional and modified ultrafiltration in adult patients. Ann Thorac Surg. 2001 ; 71: 684-693
11. Chew MS. Does modified ultrafiltration reduce the systemic inflammatory response to cardiac surgery with cardiopulmonary bypass?. Perfusion. 2004 ; 19: 57-60
12. Gummert JF, Funkat A, Beckmann A, et al. Cardiac surgery in Germany during 2010. A report on behalf of the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg. 2011 ; 59: 259-267
13. Wagner DR, McTiernan C, Sanders VJ, et al. Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart. Circulation. 1998 ; 97: 521-524
14. Von Haehling S, Schefold JC, Lainscak M, et al. Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Fail Clin. 2009 ; 5: 49-60
15. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000 ; 36: 1587-1593
16. Deliargyris EN, Raymond RJ, Theoharides TC, et al. Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure. Am J Cardiol. 2000 ; 86: 913-918
17. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996 ; 93: 704-711
18. Gómez-Jiménez J, Salgado A, Mourelle M, et al. L-arginine: nitric oxide pathway in endotoxemia and human septic shock. Crit Care Med. 1995 ; 23: 253-258
19. Tassani P, Richter JA, Eising GP, et al. Influence of combined zero-balanced and modified ultrafiltration on the systemic inflammatory response during coronary artery bypass grafting. J Cardiothorac Vasc Anesth. 1999 ; 13: 285-291
20. Grünenfelder J, Zünd G, Schoeberlein A, et al. Modified ultrafiltration lowers adhesion molecule and cytokine levels after cardiopulmonary bypass without clinical relevance in adults. Eur J Cardiothorac Surg. 2000 ; 17: 77-83
21. Bogǎ M, Islamoǧlu, Badak I, et al. The effects of modified hemofiltration on inflammatory mediators and cardiac performance in coronary artery bypass grafting. Perfusion. 2000 ; 15: 143-150
22. Lew WY, Ryan J, Yasuda S. Lipopolysaccharide induces cell shrinkage in rabbit ventricular cardiac myocytes. Am J Physiol. 1997 ; 272: 2989-2993
23. Starr RG, Lader AS, Phillips GC, et al. Direct action of endotoxin on cardiac muscle. Shock. 1995 ; 3: 380-384
24. Weber CF, Jámbor C, Strasser C, et al. Normovolemic modified ultrafiltration is associated with better preserved platelet function and less postoperative blood loss in patients undergoing complex cardiac surgery: a randomized and controlled study. J Thorac Cardiovasc Surg. 2011 ; 141: 1298-1304
25. Warren OJ, Smith AJ, Alexiou C, et al. The inflammatory response to cardiopulmonary bypass: part 1 - mechanisms of pathogenesis. J Cardiothorac Vasc Anesth. 2009 ; 23: 223-231
26. Videm V, Svennevig JL, Fosse E, et al. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg. 1992 ; 103: 806-813
27. Fitch C, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation. 1999 ; 100: 2499-2506